Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNOTHERAPY

Targeting the cancer mutanome of breast cancer

A metastatic hormone receptor–positive breast cancer, usually resistant to immunotherapy, is successfully treated with tumor-infiltrating lymphocytes enriched for neoantigen reactivity, underscoring the broad potential of this immunotherapeutic approach.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Adoptive T cell therapy successfully treats a metastatic hormone receptor–positive breast cancer.

References

  1. Campbell, B. B. et al. Cell 171, 1042–1056.e1010 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Alvarez, B., Barra, C., Nielsen, M. & Andreatta, M. Proteomics https://doi.org/10.1002/pmic.201700252 (2018).

  3. Efremova, M., Finotello, F., Rieder, D. & Trajanoski, Z. Front. Immunol. 8, 1679 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dudley, M. E. et al. Science 298, 850–854 (2002).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Rosenberg, S. A. Nat. Rev. Clin. Oncol. 8, 577–585 (2011).

    Article  PubMed  CAS  Google Scholar 

  6. Goodman, A. M. et al. Mol. Cancer Ther. 16, 2598–2608 (2017).

    Article  PubMed  CAS  Google Scholar 

  7. Schumacher, T. N. & Hacohen, N. Curr. Opin. Immunol. 41, 98–103 (2016).

    Article  PubMed  CAS  Google Scholar 

  8. Zacharakis, N. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0040-8 (2018).

  9. Bobisse, S. et al. Nat. Commun. 9, 1092 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Robbins, P. F. et al. Nat. Med. 19, 747–752 (2013).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Kreiter, S. et al. Nature 520, 692–696 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Chowell, D. et al. Science 359, 582–587 (2018).

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author thanks all colleagues and scientists who over the years have shared ideas and concepts and have worked diligently to develop cell therapy and vaccination for cancer, bringing it to the forefront of immunotherapy.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Laszlo G. Radvanyi.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Radvanyi, L.G. Targeting the cancer mutanome of breast cancer. Nat Med 24, 703–704 (2018). https://doi.org/10.1038/s41591-018-0065-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0065-z

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer